NATACYN
LOE Approachingnatamycin
NDAOPHTHALMICSUSPENSIONPriority Review
Approved
Oct 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
NATACYN (natamycin) is clinical pharmacology: natamycin is a tetraene polyene antibiotic derived from streptomyces natalensis . First approved in 1978.
Drug data last refreshed 1h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NATACYN (natamycin) is a tetraene polyene antibiotic ophthalmic suspension approved in 1978 for fungal eye infections. It works by binding to fungal cell membrane sterols, disrupting permeability and causing fungal cell death. The drug is effective against Candida, Aspergillus, Fusarium, and other fungi but does not achieve systemic absorption.
$0.767MPart D
LOE ApproachingLegacy product with minimal commercial activity; small team focus likely on maintenance and generic transition.
Mechanism of Action
CLINICAL PHARMACOLOGY: Natamycin is a tetraene polyene antibiotic derived from Streptomyces natalensis . It possesses in vitro activity against a variety of yeast and filamentous fungi, including Candida, Aspergillus, Cephalosporium, Fusarium and Penicillium . The mechanism of action appears to be…
Pharmacologic Class:
Polyene Antimicrobial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.